Table 5.
No. | Publication | Age | Sex | Condition | Treatments | Intervention | Results | Duration of Treatment before NAb Detection |
---|---|---|---|---|---|---|---|---|
1 | Borodic32 | 48 | F | Facial lines | 1–14 | ONA | Cycles 1–14: response lasted for 3–4 mo | Unclear when NAb test was done. Duration (first to last treatment): 72 mo |
>14 | ONA | |||||||
Cycle >14: no response | ||||||||
2 | Borodic33 | 44 | F | Facial lines | 1–14 | ONA 30–50 U | Cycle 15: no response, no effect on forced frown | Unclear when NAb test was done. Duration (first to last treatment): 60+ mo |
15 | ONA 100 U | |||||||
3 | Dressler et al19 | 53 | F | Facial lines | 1–10 | ABO 10–180 MU | Cycles 1–5: normal response | NAb detected (7.0 mU/mL) at cycle 10 |
Cycles 6–9: PSNR | ||||||||
Cycle 10: CSNR | ||||||||
4 | Dressler, 201019 | 46 | F | Facial lines | 1–3 | ONA 80 MU | Cycle 1: normal response | NAb detected (2.7 mU/ml) at cycle 6 |
4 | ||||||||
5–6 | BoNT–B | Cycle 2: PSNR | ||||||
7–9 | ||||||||
ONA 40–136 MU | Cycle 3: CSNR | |||||||
Cycles 5–6: CSNR | ||||||||
BoNT–B | ||||||||
5 | Dressler et al19 | 51 | F | Facial lines | 1–9 | ABO 30 MU | Cycles 1–11: normal response | NAb detected (1.0 mU/mL) at cycle 12, and (>10.0 mU/mL) at cycle 13 |
10–13 | ONA 30 MU | Cycle 12: PSNR | ||||||
Cycle 13: CSNR | ||||||||
6 | Dressler et al19 | 45 | F | Facial lines | 1–6 | ABO 25–105 MU | Cycle 3: PSNR | NAb detected (>10.0 mU/ml) at cycle 7 |
7 | INCO 33 MU | Cycle 5: CSNR | ||||||
7 | Lee17 | 20 | F | Masseteric hypertrophy | 1–6 | ONA 180 U | Cycles 1–3: response lasted for 4–5 mo | >18 mo |
7 | ABO 180 U | |||||||
Cycles 4–5: response lasted for 1.5 mo | ||||||||
Cycles 6–7: no response | ||||||||
8 | Stengel and Bee18 | 41 | F | Glabellar lines | 1–5 | ABO | Cycles 1–2: response lasted for 4–8 mo | 72 mo |
6–8 | ONA 9–28 U | |||||||
9–11 | INCO 20–44 U | Cycles 3–11: response lasted for 3–4 wk | ||||||
9 | Stephan et al40 | 51 | F | Facial lines | 1–3 | ONA, ABO | Cycles 1–3: partial response (<2 mo), required high-dose booster injections | NAb testing was not available |
NR | ONA 75 U | |||||||
NR | ||||||||
INCO | ||||||||
Cycle >3: partial response with even shorter duration of efficacy | ||||||||
10 | Torres et al41 | 55 | F | Facial rejuvenation | 1 | ONA 33 U | Cycle 1: no response | 2 mo |
2 | ABO 80 SU | Cycle 2: mild response lasting 3 mo | ||||||
11 | Torres et al41 | 54 | F | Facial rejuvenation | 1–8 | ABO 25–180 U | Cycles 1–7: normal response | Unclear when NAb test was done. |
9 | ||||||||
10 | ONA 70 U | |||||||
Cycle 8: loss of efficacy | ||||||||
11 | ABO 120 U | |||||||
INCO 69 U | Cycle 9: little treatment effect | |||||||
Cycle 10: no effect after 4 wk | ||||||||
Cycle 11: no effect after 2 wk | ||||||||
12 | Torres et al41 | 43 | F | Facial rejuvenation | 1–6 | ABO 100–260 U | Initial response lasted for 6–8 mo, decreased to 3 mo at later treatments | Unclear when NAb test was done. Duration (first to last treatment): 96 mo |
13 | Torres et al41 | 38 | M | Facial rejuvenation | 1–3 | ABO 120–250 U | Cycle 3: CSNR | Unclear when NAb test was done. Duration (first to last treatment): 36 mo |
CSNR, complete secondary nonresponse; F, female; M, male; MU, mouse unit; NR, not reported; PSNR, partial secondary nonresponse; SU, speywood unit; U, unit.